Joinn Laboratories (China) Co., Ltd. is a non-clinical contract research organization (CRO) specializing in drug safety assessment. Founded in 1995, the company provides pharmacology and toxicology evaluation services for drugs, adhering to international standards such as FDA and ICH guidelines. Its core business includes non-clinical studies, clinical trial services, and research model businesses, with facilities in Beijing and Suzhou that hold OECD GLP certification. The company serves pharmaceutical clients in China, the United States, and other regions, offering regulatory-compliant evaluation reports to agencies including the NMPA and FDA. Key subsidiaries include JOINN (Beijing) Biotechnology Ltd. and JOINN Clinical (Suzhou) Co., Ltd.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Diagnostics & Research Homepage joinnlabs.com
Sector Healthcare IR page joinnlabs.com/investor.php
Tags
non-clinical cro, drug safety assessment, pharmacology, toxicology, glp compliance, clinical trial services, research models, pharmaceutical r&d, JOINN (Beijing) Biotechnology Ltd., JOINN Clinical (Suzhou) Co. Ltd.
Press page —

Metrics

Valuation  
Market cap HK$ 12.152B
Market cap (USD) $ 1.549B
P/E 43.10
PEG —
P/BV 1.15
P/S 6.10
P/OCF 13.99
P/FCF —
Dividend yield 0.72%
Turnover / mcap 0.60%
Returns  
ROE 3.6%
ROI 3.6%
ROIC 4.1%
Profit margin 18.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -34.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 1.658B 2.018B 2.376B 2.268B 1.517B 1.076B 639.379M
Net profit 297.841M 74.075M 396.993M 1.074B 557.46M 312.95M 187.838M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 36.13 9.18 11.56 48.38 44.34 118.39 —
Price performance 12m 3.02 -0.2 -0.77 0.04 -0.6 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2026 THIRD QUARTERLY REPORT Bull 4 Bear 0 Results

Prompts

Joinn Laboratories (China) Co., Ltd. (ticker 6127), listed in Hong Kong.

ETFs Holding Joinn Laboratories (China) Co., Ltd.

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 12,500 $ 35.047K Nov 16, 2026
AVSE 0.01% 6,500 $ 18.225K Nov 16, 2026
DFEM 0.00% 105,300 $ 327.525K Nov 12, 2026
DFSE 0.00% 5,700 $ 17.729K Nov 12, 2026
DFAX 0.00% 43,700 $ 135.924K Nov 12, 2026
DFAE 0.00% 26,700 $ 83.048K Nov 12, 2026
AVEM 0.00% 412,600 $ 1.157M Nov 16, 2026